Atherly, A J <br/><br/>
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.  [electronic resource] 

 -  British journal of cancer  Mar 2012 
 - 1100-6 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2012.60  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anaplastic Lymphoma Kinase<br/>Antineoplastic Agents--pharmacology<br/>Biomarkers, Tumor--antagonists & inhibitors<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cost-Benefit Analysis<br/>Crizotinib<br/>Drug Resistance, Neoplasm<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Models, Biological<br/>Molecular Targeted Therapy--economics<br/>Precision Medicine--economics<br/>Pyrazoles--pharmacology<br/>Pyridines--pharmacology<br/>Quality of Life<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors